Metraipolis › archive › dc_219c5e5df285
Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study — Europe PMC PMID:41406177
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41406177
- DOI
- 10.1371/journal.pmed.1004651
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T13:58:09.804Z
- SHA-256 of the archived text
d837e7812da215679f711d12460f6e5c762a61bc7db5683f714fcd7a8944cafa- Stable URL of this page
https://metraipolis.com/documento/dc_219c5e5df285
How to cite
Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study — Europe PMC PMID:41406177 — Europe PMC (en), https://europepmc.org/article/MED/41406177 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_219c5e5df285 (Metraipolis archive dc_219c5e5df285, sha256 d837e7812da215679f711d12460f6e5c762a61bc7db5683f714fcd7a8944cafa)
BibTeX
@misc{dc219c5e5df285,
title = {Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study — Europe PMC PMID:41406177},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41406177},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_219c5e5df285; sha256 d837e7812da215679f711d12460f6e5c762a61bc7db5683f714fcd7a8944cafa},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41406177. Agents can read the archived copy with the MCP tool read_document.